Search / 14207 results found

from
to
  • Updated

IRVINE, Calif., Sept. 17, 2021 /PRNewswire-HISPANIC PR WIRE/ -- The introduction of Kia America's first dedicated all-electric model – the all-new 2022 EV6 Crossover – continues as the brand once again partnered with the 73RD EMMY® AWARDS and NBCUniversal's America's Got Talent. The initiatives follow the May 2021 launch of the EV6 in New York City's Times Square and will continue to not only introduce the EV6 to U.S. consumers, but also introduce the transformed Kia America brand to the U.S. market through an all-new, 60-second creative campaign that debuts during the 73RD EMMY® AWARDS.  

  • Updated

LONG BEACH, Calif. and TORONTO, Sept. 17, 2021 /CNW/ - Glass House Brands Inc. ("Glass House" or the "Company") (NEO: GLAS.A.U) (NEO: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest-growing, vertically integrated cannabis companies in the U.S., today announced that it has sent a letter to shareholders from Chairman and Chief Executive Officer Kyle Kazan. The letter can be accessed on the Company's investor relations website and under the Company's profile on SEDAR at www.sedar.com.

  • Updated

SAN FRANCISCO and SUZHOU, China, Sept. 17, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the interim analysis results of the Phase 3 ORIENT-15 study evaluating sintilimab in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma (ESCC) were released today in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021 (Abstract # LBA52).

  • Updated

SAN FRANCISCO and SUZHOU, China, Sept. 17, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced the interim analysis results of the Phase 3 ORIENT-16 study evaluating sintilimab in combination with chemotherapy compared to chemotherapy alone for the first-line treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma in an oral presentation at the ESMO (European Society for Medical Oncology) Congress 2021 (Abstract # LBA53).

  • Updated

BEVERLY HILLS, Calif., Sept. 17, 2021 /PRNewswire-PRWeb/ -- Nurse Hatty was on hand to answer all the guest's questions and gift her unique SCRIPT® brands of products, including Kegel Script®, Ketone Script®, Uri-10 Script®, pH Script, UTI Script, Wrinkle Script, as well as Nip' N Lift™. The biggest craze was Kegel Script™ X, a Kegel Exercise System for Women, and Ketone Script™, Ketone Test Strips that helps low-fat dieters gauge the diet's success. Wrinkle Script and Nip 'N Lift™ were also well received.

  • Updated

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that on September 15, 2021, the Compensation Committee of Sutro's Board of Directors granted restricted stock unit awards (RSUs) representing an aggregate of 150,000 shares of Sutro common stock and stock options to purchase an aggregate of 145,000 shares of Sutro common stock to 3 new employees. The grants were made as an inducement material to the employees' acceptance of employment with Sutro and were approved by the Compensation Committee of Sutro's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Updated

FONTANA, Calif., Sept. 17, 2021 /PRNewswire/ -- Members of United Steelworkers Local 7600, which represents 7,400 workers across 72 Kaiser Permanente locations in Southern California, today announced that they would pause participation in their longstanding labor-management partnership. This comes after the health care giant repeatedly signaled that it is not taking the partnership seriously, jeopardizing the system's ability to keep workers and patients safe.

  • Updated

LOS ANGELES, Sept. 17, 2021 /PRNewswire-PRWeb/ -- Marshall W. Waller first compiled this exam study guide while preparing for California Family Law Specialist certification. Since then, this text has been continually updated to serve as a helpful tool for attorney's taking the California Certified Family Law Specialist examination. It is written specifically for the education of family lawyers. This guide is not only a valuable resource for preparation to take the family law specialist exam; it is also a day-to-day practice guide for California family law attorneys. This exclusive lawyer-to-lawyer book provides a privileged view of California family law.

  • Updated

LOS ANGELES, Sept. 17, 2021 /PRNewswire/ -- Staley Point Capital ("Staley Point"), a value-add investor focused on infill industrial properties, today announced the acquisition of 2187 Garfield, a 132,000 square-foot cross-dock warehouse in Commerce, CA, for $38.5 million, or $292 per square foot.

  • Updated

CARLSBAD, Calif., Sept. 17, 2021 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced the closing of its initial public offering of 12,420,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,620,000 additional shares, at an initial public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Tyra, were $198,720,000 million. Tyra's common stock is listed on the Nasdaq Global Select Market under the ticker symbol "TYRA."